Searchable abstracts of presentations at key conferences in endocrinology

ea0041gp16 | Adrenal (1) | ECE2016

Increased morbidity and hospital admissions in patients with adrenal insufficiency

Stewart Paul M , Biller Beverly MK , Marelli Claudio , Gunnarsson Candace , Ryan Michael , Johannsson Gudmundur

Introduction: Patients with adrenal insufficiency (AI) (primary (PAI), secondary to pituitary disease (PIT) and congenital adrenal hyperplasia (CAH)) have reduced life expectancy with reported standardized mortality ratios of ~2:1 but given the rarity of AI, the underlying explanation remains largely unknown.Objective: To evaluate patient characteristics, prevalence of concomitant conditions and hospitalization incidence in patients with AI compared to a...

ea0081rc7.5 | Rapid Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Osilodrostat therapy improves physical manifestations of hypercortisolism in patients with cushing’s disease: findings from the phase III LINC 3 study

Pivonello Rosario , Fleseriu Maria , Akira Shimatsu , Newell-Price John , Auchus Richard , Feelders Richard , Pedroncelli Alberto , Piacentini Andrea , Biller Beverly MK

Background: Improving physical manifestations of hypercortisolism is an important treatment goal for patients with Cushing’s disease (CD). In the Phase III LINC 3 study (NCT02180217), osilodrostat therapy, a potent oral 11β-hydroxylase inhibitor, rapidly normalised mean urinary free cortisol (mUFC) in most patients with CD and sustained control of mUFC over a median treatment period of 130 weeks (W). Here we describe concomitant improvements in physical manifestation...

ea0063gp53 | Acromegaly and GH | ECE2019

Efficacy and safety of once-weekly somapacitan in adult growth hormone deficiency (AGHD) confirmed in a 53-week REAL-1 trial extension

Johannsson Gudmundur , Gordon Murray , Rasmussen Michael Hojby , Hakonsson Ida Holme , Svaerke Claus , Tahara Shigeyuki , Takano Koji , Biller Beverly MK

Background: Following the 34-week, double-blind, placebo-controlled main phase of REAL-1 (NCT02229851), this open-label trial extension evaluated efficacy and safety of somapacitan in patients aged 23–79 years with AGHD, for an additional 52 weeks (8 weeks’ dose titration followed by 44 weeks’ fixed dose treatment; 86 weeks’ treatment in total).Methods: Patients completing the main trial entered the extension: 1) somapacitan-treated p...

ea0063gp166 | Obesity (1) | ECE2019

Results from the phase 3 multicenter SONICS study of levoketoconazole: subgroup analysis of Cushing’s syndrome patients with diabetes mellitus

Fleseriu Maria , Pivonello Rosario , Elenkova Atanaska , Salvatori Roberto , Auchus Richard J. , Feelders Richard A. , Geer Eliza B. , Greenman Yona , Witek Przemyslaw , Cohen Frederic , Biller Beverly MK

Background: Cushing’s syndrome (CS) has numerous comorbidities, including diabetes mellitus (DM). Levoketoconazole is a ketoconazole stereoisomer in clinical trials for treatment of CS.Methods: SONICS is a prospective, open-label, phase 3 maintenance-of-benefit study in adults with confirmed CS and mean urinary free cortisol (mUFC) of ≥1.5x upper limit of normal (ULN). Repeated hospitalization due to hyperglycemia or any complication related t...

ea0037gp.22.04 | Pituitary–Therapy of Cushing's disease | ECE2015

Long-term (5 years) treatment of Cushing's disease with pasireotide

Petersenn Stephan , Salgado Luiz R , Schopohl Jochen , Portocarrero-Ortiz Lesly , Arnaldi Giorgio , Lacroix Andre , Ravichandran Shoba , Kandra Albert , Bagulho Teresa , Biller Beverly MK

Background: In a large 12-month Phase III study, pasireotide led to rapid and sustained decreases in UFC and provided clinical benefit in patients with Cushing’s disease. Here, we report data following an open-label, open-ended extension.Methods: 162 patients with persistent/recurrent or de novo Cushing’s disease were randomized in the core study. 58 patients with mean UFC≤ULN or clinical benefit at month 12 entered the extension...

ea0056oc12.4 | Novel aspects of puberty development and Cushing's disease | ECE2018

Late-night salivary cortisol (LNSC) levels in a Phase III study of long–acting pasireotide in patients with Cushing’s disease (CD)

Newell-Price John , Pivonello Rosario , Tabarin Antoine , Fleseriu Maria , Witek Przemyslaw , Gadelha Monica , Petersenn Stephan , Tauchmanova Libuse , Ravichandran Shoba , Roughton Michael , Lacroix Andre , Biller Beverly MK

Introduction: LNSC has shown high sensitivity and specificity for the initial diagnosis of CD and detection of disease recurrence; however, the use of LNSC to monitor medical treatment of CD is not well established. The results of an exploratory analysis evaluating changes in LNSC in CD patients receiving long-acting pasireotide during a Phase III study (CSOM230G2304; Lacroix et al. Lancet Diabetes Endocrinol 2018) are reported here.Methods: Pat...